sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

RespireRx Pharmaceuticals Inc. is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. All of the Company’s current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress.

Eiken Chemical Co., Ltd. engages in the manufacture and sale of clinical diagnostics products and equipment. It operates through following business divisions: Clinical Diagnostics and Testing of Food and Environment. The Clinical Diagnostics division handles the manufacture of clinical diagnostic products and services. The Testing of Food and Environment division deals with the sale of reagents for microbiological tests on food for poisoning bacteria, and environment for contamination of work environments. Its products include fecal immunochemical testing equipment, molecular test loop-mediated isothermal amplification (LAMP), immunological and serological reagents, and rapid diagnostic tests such as IMMUNOCATCH Norovirus, IMMUNOCATCH Legionella, and IMMUNOCATCH Streptococcus pneumoniae. The company was founded on February 20, 1939 and is headquartered in Tokyo, Japan.

Anyu Biotechnology (Hangzhou) Co., Ltd., established on 2020-04-20, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export;Sales of Class I Medical Devices;Machinery sales;Sales of mechanical and electrical equipment;Specialty Chemicals Sales(Free of Hazardous Chemicals);Chemical product sales(No licensed chemical products);Instrument sales;Health Consulting Services(Does not include medical services);Engineering and Technology Research and Experimental Development;HR Services(Excludes job brokerage activities,Labor dispatch service);Sales of Class II Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:pharmaceutical production;food sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Provides pharmaceutical research and development services

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Phenomenome Discoveries, Inc. provides human health research tools to discover metabolite biomarkers. Its services include discovery, analytics, informatics, collaborators and analytical services. The company was founded by John Hyshka and Dayan B. Goodenowe in 2000 and is headquartered in Saskatoon, Canada.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

The Group's principal activity is to produce pharmaceuticals and chemicals. The operations are carried out through the following divisions: Pharmaceuticals; Bio chemical; Chemicals; Food and Other. Pharmaceuticals include ethical drugs, bulk pharmaceuticals and biological research. Bio chemicals deal with biochemical diagnostic reagents, animal health products, agrochemicals and fertilizers. Chemicals includes solvents, plasticizes and their raw materials, detergent raw materials and specialty chemicals. Food includes alcoholic beverages, alcohol, seasonings, confectionery, baking ingredients and processed foods. Others include wholesale, commodity distribution and installation of facilities.

AWD.pharma GmbH & Co. KG develops and markets generic drugs. It manufactures medicines for the treatment of cardiovascular diseases, pain relief, and diseases of the central nervous system. The company also wholesales pharmaceutical products through its subsidiary O.R.C.A.pharm GmbH. AWD.pharma was founded in 2001 and is headquartered in Radebeul, Germany.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Manufactures chemicals